Skip to main content

Ag Genomics: Monsanto Closes Cereon, Keeps Millennium Partnership

Premium

Cereon Genomics, a wholly owned subsidiary of Monsanto and a product of a long-term collaboration with Millennium Pharmaceuticals, has been shut down. The Cambridge, Mass., facility, home to approximately 140 employees, “will not be part of our system around mid-year,” says Monsanto spokeswoman Lori Fisher.

The decision coincides with a restructuring plan underway at Monsanto, which will cost as much as $124 million and would cut about five percent of its worldwide staff — between 600 and 700, the majority of which would be in New Zealand, southeastern Asia, Australia, and North America, Fisher says. Some of the Cereon staff will assume positions within Monsanto, but she could not say how many.

“It’s a tough decision,” Fisher says. “Cereon has been extraordinarily successful … in structural and functional genomics.”

Fisher stressed that the decision to shut down Cereon, which was launched in 1997, has not affected Monsanto’s broader collaboration with Millennium. Monsanto also has ongoing relationships with Affymetrix, Bangalore Genomics, Ceres, danforth plant sciences Center, IBM, Incyte, Mystic Genomics, Orchid BioSciences, Paradigm, Rosetta, and Third Wave Technologies.

— Kirell Lakhman

 

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.